Updates
** Shares of medical equipment maker West Pharmaceuticals WST.N fall 3.7% to $210.19 in morning trade
** Company expects its HVP components business to grow mid-single digits instead of mid-to-high single digits, as it previously forecast
** Forecast cut came as one of WST's customers switched the type of component they were purchasing, which can currently only be supplied from one manufacturing facility, while the previous one could be sourced from multiple facilities
** This results in some stock-outs / delay in shipping this product to the customer - Nephron Research
** The business includes products to improve shelf life of packaged drugs, among others
** Company raised its annual adj EPS forecast to $6.15 to $6.35, up from $6 to $6.20
** WST reports Q1 adj. profit of $1.45/share, vs analysts' estimate of $1.23/share
** As of last close, WST stock down 33.4% YTD
(Reporting by Padmanabhan Ananthan and Puyaan Singh)
((Padmanabhan.Ananthan@thomsonreuters.com))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。